keyword
MENU ▼
Read by QxMD icon Read
search

UDCA

keyword
https://www.readbyqxmd.com/read/28749455/primary-biliary-cholangitis-alters-functional-connections-of-the-brain-s-deep-gray-matter
#1
Victoria A L Mosher, Mark G Swain, Jack X Q Pang, Gilaad G Kaplan, Keith A Sharkey, Glenda M MacQueen, Bradley G Goodyear
OBJECTIVES: Fatigue, itch, depressed mood, and cognitive impairment significantly impact the quality of life of many patients with primary biliary cholangitis (PBC). Previous neuroimaging studies of non-hepatic diseases suggest that these symptoms are often associated with dysfunction of deep gray matter brain regions. We used resting-state functional magnetic resonance imaging (rsfMRI) to determine whether PBC patients exhibit altered functional connections of deep gray matter. METHODS: Twenty female non-cirrhotic PBC patients and 21 age/gender-matched controls underwent rsfMRI...
July 27, 2017: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/28714405/emerging-targets-to-relieve-fat-stress-induced-liver-diseases-udca-tocotrienol-%C3%AF-3-pufas-and-igy-targeted-npc1l1-cholesterol-transporter
#2
Ji-Young Cha, Jong-Min Park, Ho-Jae Lee, Jin-Sik Bae, Young-Min Han, Byung-Chul Oh, Kwang Hyun Ko, Ki-Baik Hahm
Fat stress-induced liver disease is a hepatic manifestation of metabolic syndrome initiated by excess fat accumulation and encompasses a wide spectrum of diseases from non-alcoholic fatty liver disease to non-alcoholic steatohepatitis, a precursor lesion progressing to more aggressive liver cirrhosis and hepatocellular carcinoma. Although the incidence of these fat stress-induced liver diseases is rapidly increasing worldwide in parallel with the growing epidemics of obesity and metabolic diseases, its exact pathogenesis is not well defined...
July 14, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28708871/ursodeoxycholic-acid-inhibits-the-proliferation-of-colon-cancer-cells-by-regulating-oxidative-stress-and-cancer-stem-like-cell-growth
#3
Eun-Kyung Kim, Jae Hee Cho, EuiJoo Kim, Yoon Jae Kim
INTRODUCTION: The regulation of reactive oxygen species (ROS) exists as a therapeutic target for cancer treatments. Previous studies have shown that ursodeoxycholic acid (UDCA) suppresses the proliferation of colon cancer cells. The aim of this study was to evaluate the effect of UDCA upon the proliferation of colon cancer cells as a direct result of the regulation of ROS. METHOD: Colon cancer cell lines (HT29 and HCT116) were treated with UDCA. The total number of cells and the number of dead cells were determined using cell counters...
2017: PloS One
https://www.readbyqxmd.com/read/28676994/cimetidine-lactulose-therapy-ameliorates-erythropoietic-protoporphyria-related-liver-injury
#4
Naoyuki Fujimori, Michiharu Komatsu, Naoki Tanaka, Mai Iwaya, Hajime Nakano, Ayumi Sugiura, Tomoo Yamazaki, Soichiro Shibata, Yugo Iwaya, Takashi Muraki, Yuki Ichikawa, Takefumi Kimura, Satoru Joshita, Takeji Umemura, Akihiro Matsumoto, Eiji Tanaka
A 21-year-old Japanese man was admitted to our hospital because of severe abdominal pain and jaundice. He had been suffering from abdominal pain attacks and liver dysfunction since 18 years of age. Liver histology showed amorphous brown deposits in the sinusoidal space and significant periportal fibrosis without apparent hepatitis. Increased protoporphyrin in serum and feces and ferrochelatase gene mutation confirmed the final diagnosis of erythropoietic protoporphyria (EPP). Since ursodeoxycholic acid (UDCA) intake and glucose infusion are insufficient to ameliorate jaundice and abdominal attacks, cimetidine and lactulose were added in order to suppress hepatic delta-aminolevulinic acid synthase and limit re-absorption of protoporphyrin, respectively...
July 4, 2017: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/28669591/primary-biliary-cholangitis-old-and-novel-therapy
#5
Annarosa Floreani, Chiara Mangini
Primary biliary cholangitis (PBC), formerly called primary biliary cirrhosis, is a chronic cholestatic liver disease that progresses slowly to end-stage liver disease. The first Food and Drug Administration (FDA)-approved treatment for PBC was ursodeoxycholic acid (UDCA). This treatment slows the progress of the disease, but approximatively 30-40% of patients fail to respond to UDCA. A number of options are under investigation as second line treatment. Obeticholic acid (OCA), a Farnesoid X Receptor agonist, has been approved in May 2017 by FDA for patients non responders or intolerant to UDCA...
June 29, 2017: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/28665991/anti-inflammatory-effects-of-ursodeoxycholic-acid-by-lipopolysaccharide-stimulated-inflammatory-responses-in-raw-264-7-macrophages
#6
Wan-Kyu Ko, Soo-Hong Lee, Sung Jun Kim, Min-Jae Jo, Hemant Kumar, In-Bo Han, Seil Sohn
PURPOSE: The aim of this study was to investigate the anti-inflammatory effects of Ursodeoxycholic acid (UDCA) in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. METHODS: We induced an inflammatory process in RAW 264.7 macrophages using LPS. The anti-inflammatory effects of UDCA on LPS-stimulated RAW 264.7 macrophages were analyzed using nitric oxide (NO). Pro-inflammatory and anti-inflammatory cytokines were analyzed by quantitative real time polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA)...
2017: PloS One
https://www.readbyqxmd.com/read/28637315/attenuated-effects-of-bile-acids-on-glucose-metabolism-and-insulin-sensitivity-in-a-male-mouse-model-of-prenatal-undernutrition
#7
Huijuan Ma, Vicencia M Sales, Ashley R Wolf, Sathish Subramanian, Tucker J Matthews, Michael Chen, Aparna Sharma, Walt Gall, Wim Kulik, David E Cohen, Yusuke Adachi, Nicholas W Griffin, Jeffrey I Gordon, Mary-Elizabeth Patti, Elvira Isganaitis
Prenatal undernutrition and low birth weight are associated with risk of type 2 diabetes and obesity. Prenatal caloric restriction results in low birth weight, glucose intolerance, obesity, and reduced plasma bile acids (BA) in offspring mice. Since BAs can regulate systemic metabolism and glucose homeostasis, we hypothesized that BA supplementation could prevent diet-induced obesity and glucose intolerance in this model of developmental programming. Pregnant dams were food restricted by 50% from gestational days 12...
June 15, 2017: Endocrinology
https://www.readbyqxmd.com/read/28602806/the-overall-fatty-acid-absorption-controlled-by-basolateral-chylomicron-excretion-under-regulation-of-p-jnk1
#8
Wolfgang Stremmel, Simone Staffer, Andreas Wannhoff, Anita Pathil
Suppression of fatty acid absorption is one goal to fight obesity. However, the responsible molecular mechanism is poorly understood. Aim of the present study was the search for the key regulator of the overall fatty acid absorption mechanism and its pharmaceutical modulation. As experimental tool we employed the polarized human intestinal tumor derived cell line CaCo2. Here we showed that influx of fatty acids is mediated by an apical heterotetrameric plasma membrane protein complex of which the calcium-independent membrane phospholipase A2 (iPLA2ß) is one constituent...
June 6, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28596137/reshaping-antibiotics-through-hydrophobic-drug-bile-acid-ionic-complexation-enhances-activity-against-staphylococcus-aureus-biofilms
#9
Stefano Giovagnoli, Donatella Pietrella, Lanfranco Barberini, Claudio Santi, Andrea Carotti, Alessandro di Michele, Maurizio Ricci
The antibiotic era is on the verge of a profound change and facing a ground shaking crisis. The frequent failures of antibiotic treatments are often associated with biofilm formation, which is responsible for chronic infections, exacerbation as well as reinfection. So far, albeit the large number of valuable strategies employed to combat biofilm formation, little success has been recorded. In this work, we propose a simple approach, based on hydrophobic ionic complexation with the bile acids, deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA), to enhance anti-biofilm activity of well-known antibiotics, namely kanamycin (K), amikacin (A) and vancomycin (V)...
June 6, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28539269/ursodeoxycholic-acid-attenuates-experimental-autoimmune-arthritis-by-targeting-th17-and-inducing-pampk-and-transcriptional-corepressor-smile
#10
Eun-Jung Lee, Jeong-Eun Kwon, Min-Jung Park, Kyung-Ah Jung, Da-Som Kim, Eun-Kyung Kim, Seung Hoon Lee, Jong Young Choi, Sung-Hwan Park, Mi-La Cho
BACKGROUND: Ursodeoxycholic acid (UDCA) has been known that UDCA has prominent effects on liver, however, there is little known about its influence on autoimmune disease. Here, the benefit of UDCA on arthritis rheumatoid (RA) in vivo was tested. METHODS: RA mouse were induced using collagen II (CIA, collagen induced arthritis) where the disease severity or UDCA-related signaling pathway such as AMP-activated protein kinase (AMPK) or small heterodimer partner interacting leucine zipper protein (SMILE) was evaluated by westerblot and immunohistochemical staining...
August 2017: Immunology Letters
https://www.readbyqxmd.com/read/28529147/norursodeoxycholic-acid-improves-cholestasis-in-primary-sclerosing-cholangitis
#11
Peter Fickert, Gideon M Hirschfield, Gerald Denk, Hanns-Ulrich Marschall, Istvan Altorjay, Martti Färkkilä, Christoph Schramm, Ulrich Spengler, Roger Chapman, Annika Bergquist, Erik Schrumpf, Frederik Nevens, Palak Trivedi, Florian P Reiter, Istvan Tornai, Emina Halilbasic, Roland Greinwald, Markus Pröls, Michael P Manns, Michael Trauner
Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties in a preclinical PSC mouse model. AIM: To evaluate the safety and efficacy of 3 doses of oral norUDCA (500mg/d, 1000mg/d or 1500 mg/d) compared with placebo in PSC in a RCT including 38centers from 12European countries...
May 18, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28517369/treatment-of-primary-biliary-cholangitis-ursodeoxycholic-acid-non-responders-a-systematic-review
#12
Duminda Suraweera, Harman Rahal, Melissa Jimenez, Matthew Viramontes, Gina Choi, Sammy Saab
BACKGROUND: Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic cholestatic liver disease characterized by an immune mediated destruction of intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) has been the primary medication for the treatment of PBC, resulting in improved liver tests, resolution of symptoms and increased transplant free survival. However, not all patients respond to UDCA. The aim of this systematic review is to provide an evidence based assessment of the medications that have been studied in patients who are refractory to UDCA...
May 18, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28514401/-differentiation-therapy-for-non-acidic-gastroesophageal-reflux-disease
#13
N B Lishchuk, V I Simanenkov, S V Tikhonov
AIM: To investigate the clinical and pathogenetic features of the non-acidic types of gastroesophageal reflux disease (GERD) and to evaluate the impact of combined therapy versus monotherapy on the course of this disease. SUBJECTS AND METHODS: The investigation enrolled 62 patients with non-acidic GERD. The follow-up period was 6 weeks. The patients were divided into 2 groups: 1) weakly acidic gastroesophageal refluxes (GER); 2) weakly alkaline GER. Then each group was distributed, thus making up 4 groups: 1) 19 patients with weakly acidic GER who received monotherapy with rabeprazole 20 mg/day; 2) 21 patients with weakly acidic GER had combined therapy with rabeprazole 20 mg and itopride; 3) 8 patients with weakly alkaline GER who received ursodeoxycholic acid (UDCA) monotherapy; and 4) 14 patients with weakly alkaline GER who had combined therapy with UDCA and itopride, The clinical symptoms of the disease, the endoscopic pattern of the upper gastrointestinal tract (GIT) mucosa, histological changes in the esophageal and gastric mucosa, and the results of 24-hour impedance pH monitoring were assessed over time...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28468009/what-comes-after-ursodeoxycholic-acid-in-primary-biliary-cholangitis
#14
Lin Lee Wong, Vinod S Hegade, David E J Jones
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by chronic cholestasis. Treatment with the accepted primary therapy ursodeoxycholic acid (UDCA) has been shown to be associated with delayed disease progression probably through reduced impact of cholestatic injury on the target biliary epithelial cells. Patients with inadequate response to UDCA (which can be identified through validated biochemical criteria) are at increased risk of disease progression, need for liver transplantation, and death...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/28447968/protective-effects-of-ursodeoxycholic-acid-in-experimental-corrosive-esophagitis-injury-in-rats
#15
Adem Ku Çu K, Naci Topaloglu, Sule Yildirim, Mustafa Tekin, Mesut Erbas, Hasan Ali Kiraz, Havva Erdem, Aybars Özkan
Accidental caustic ingestions are serious medical problems especially in childhood. Various treatment modalities are being used for the complications of caustic injuries such as stricture formation. The aim of this study is to establish whether ursodeoxycholic acid (UDCA) has protective effects on experimental corrosive esophagitis in rats. Twenty four Wistar-albino rats, weighing 220-240 g, were used in the study. Experimental animals were divided in three groups randomly: UDCA treatment group (Group T, n:8), control group (Group K, n: 8) and sham group (Group S, n: 8)...
2017: Annali Italiani di Chirurgia
https://www.readbyqxmd.com/read/28425413/ursodeoxycholic-acid-therapy-in-patients-with-primary-biliary-cholangitis-with-limited-liver-transplantation-availability
#16
Yazmín Karel Melchor-Mendoza, Braulio Martínez-Benítez, Aline Mina-Hawat, Gustavo Rodríguez-Leal, Ximena Duque, Segundo Moran-Villota
INTRODUCTION: There is little information on survival rates of patients with primary biliary cholangtis (PBC) in developing countries. This is particularly true in Latin America, where the number of liver transplants performed remains extremely low for patients with advanced liver disease who fulfill criteria for liver transplantation. The goal of this study was to compare survival rate of patients with PBC in developing countries who were treated with ursodeoxycholic acid (UDCA) versus survival of patients who received other treatments (OT) without UDCA, prescribed before the UDCA era...
May 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28425308/the-effect-of-molecular-weights-of-microencapsulating-polymers-on-viability-of-mouse-cloned-pancreatic-%C3%AE-cells-biomaterials-osmotic-forces-and-potential-applications-in-diabetes-treatment
#17
Armin Mooranian, Ryu Tackechi, Emma Jamieson, Grant Morahan, Hani Al-Salami
INTRODUCTION: Ideal cell-containing microcapsules should be capable of maintaining cell viability and exhibit significant structural stability to support cellular functionality. To date, such microcapsules remain unavailable, thus, this study used our well-established microencapsulating methods to examine a total of 32 different microencapsulating formulations and correlate polymers' molecular weights (Mwt) and UDCA addition, with cell viability and microcapsules' stability, postmicroencapsulation...
April 20, 2017: Pharmaceutical Development and Technology
https://www.readbyqxmd.com/read/28417463/pharmacological-interventions-for-primary-sclerosing-cholangitis-an-attempted-network-meta-analysis
#18
REVIEW
Francesca Saffioti, Kurinchi Selvan Gurusamy, Neil Hawkins, Clare D Toon, Emmanuel Tsochatzis, Brian R Davidson, Douglas Thorburn
BACKGROUND: Primary sclerosing cholangitis is a chronic cholestatic liver disease that is associated with both hepatobiliary and colorectal malignancies, which can result in liver cirrhosis and its complications. The optimal pharmacological treatment for patients with primary sclerosing cholangitis remains controversial. OBJECTIVES: To assess the comparative benefits and harms of different pharmacological interventions in people with primary sclerosing cholangitis by performing a network meta-analysis, and to generate rankings of available pharmacological interventions according to their safety and efficacy...
March 28, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28382327/proton-pump-inhibitor-is-a-risk-factor-for-recurrence-of-common-bile-duct-stones-after-endoscopic-sphincterotomy-propensity-score-matching-analysis
#19
Nobuhiko Fukuba, Shunji Ishihara, Hiroki Sonoyama, Noritsugu Yamashita, Masahito Aimi, Yoshiyuki Mishima, Tsuyoshi Mishiro, Hiroshi Tobita, Koutarou Shibagaki, Naoki Oshima, Ichiro Moriyama, Kousaku Kawashima, Tatsuya Miyake, Norihisa Ishimura, Shuichi Sato, Yoshikazu Kinoshita
Background and study aims Recurrence of common bile duct stones (CBDS) in patients treated with endoscopic sphincterotomy (ES) can lead to deterioration in their quality of life. Although the pathology and related factors are unclear, we speculated that proton pump inhibiter (PPI) administration increases the risk of CBDS recurrence by altering the bacterial mixture in the bile duct. Patients and methods The primary endpoint of this retrospective study was recurrence-free period. Several independent variables considered to have a relationship with CBDS recurrence including PPI use were analyzed using a COX proportional hazard model, with potential risk factors then evaluated by propensity score matching analysis...
April 2017: Endoscopy International Open
https://www.readbyqxmd.com/read/28382282/ursodeoxycholic-acid-induces-death-receptor-mediated-apoptosis-in-prostate-cancer-cells
#20
Won Sup Lee, Ji Hyun Jung, Radha Panchanathan, Jeong Won Yun, Dong Hoon Kim, Hye Jung Kim, Gon Sup Kim, Chung Ho Ryu, Sung Chul Shin, Soon Chan Hong, Yung Hyun Choi, Jin-Myung Jung
BACKGROUND: Bile acids have anti-cancer properties in a certain types of cancers. We determined anticancer activity and its underlying molecular mechanism of ursodeoxycholic acid (UDCA) in human DU145 prostate cancer cells. METHODS: Cell viability was measured with an MTT assay. UDCA-induced apoptosis was determined with flow cytometric analysis. The expression levels of apoptosis-related signaling proteins were examined with Western blotting. RESULTS: UDCA treatment significantly inhibited cell growth of DU145 in a dose-dependent manner...
March 2017: Journal of Cancer Prevention
keyword
keyword
96480
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"